Dernière mise à jour :
19/11/2024
Antibiotique   Oxacillin sodium  
injectable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Bactocill Etats Unis d’Amérique
Bioxalin Pérou
Bristopen Maroc
Istopen France
Lioxac Pérou
Oxacil Tunisie
Oxacilil Brésil
Oxacilina Brésil, Colombie, Equateur, Pérou, Roumanie, Vénézuela
Oxacillin Etats Unis d’Amérique
Oxacip Vénézuela
Oxalin Pérou
Oxamicin Vénézuela
Oxanon Brésil
Oxipen Vénézuela
Pebenal Vénézuela
Staphymicine Maroc
Bibliographie   injectable   Bibliographie : Oxacillin sodium  
Type Source
13 Revue Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
73 Revue Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
150 Revue Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
198 Revue Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
336 Revue Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Revue Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
371 Revue Thompson DF, Stiles ML, Allen LV, Tu YH.
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 142-145.
386 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
397 Revue Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
405 Revue Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
479 Revue Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
496 Revue Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
576 Revue Holmes CJ, Ausman RK, Walter CW, Kundsin RB.
Activity of antibiotic admixtures subjected to different freeze-thaw treatments.
Drug Intell Clin Pharm 1980 ; 14: 353-357.
604 Laboratoire Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
738 Revue Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584.
999 Revue Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1047 Revue Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Revue Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Revue Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135 Revue Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 Revue Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1705 Revue Zhang Y, Trissel LA.
Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags.
Int J Pharm Compound 2002 ; 6: 226-229.
1802 Revue Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
3227 Revue Simon B, Hancu G, Gy?resi A.
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520 Laboratoire Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3529 Laboratoire Ciprofloxacin – Summary of Product Characteristics
Hospira 2013
3549 Laboratoire Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Laboratoire Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3589 Laboratoire Oxacilline PanPharma – Résumé des caractéristiques du produits
PanPharma 2013
3638 Laboratoire Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010
3643 Laboratoire Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 Laboratoire Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3813 Revue Teibel H.M, Knoderer C.A, Nichols K.R.
Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
Hosp Pharm 2015 ; 50, 8: 710-713.

  Mentions Légales